Grafalon

Grafalon is a rabbit-derived anti‑T lymphocyte immunoglobulin for human use, supplied as an injectable solution for intravenous administration. The product contains polyclonal antibodies that target human T lymphocytes and is classified as an immunosuppressive agent. It is marketed in the European Union and is available by prescription only.

Grafalon is employed in clinical settings where modulation of the immune response is required. It is primarily used to reduce the risk of immune‑mediated complications following transplantation and related procedures.

- Prevention of acute organ transplant rejection - Treatment of graft‑versus‑host disease (GVHD) after hematopoietic stem cell transplantation - Conditioning regimen component for allogeneic stem cell transplantation - Adjunct therapy in certain autoimmune conditions under specialist supervision

Side effects of Grafalon vary in frequency and severity. Common reactions are usually mild to moderate, while serious events are less frequent but require prompt medical attention.

Common: - Fever and chills during infusion - Headache - Nausea or vomiting - Transient hypotension - Rash or mild skin erythema - Elevated liver enzymes

Serious: - Severe infusion‑related reactions (anaphylaxis, bronchospasm) - Opportunistic infections (viral, bacterial, fungal) - Cytopenias (neutropenia, thrombocytopenia) - Malignancy risk with prolonged immunosuppression - Renal impairment or acute kidney injury

Grafalon should be used with careful monitoring and consideration of patient‑specific risk factors. Important safety points include:

- Assess for active infections before initiating therapy - Monitor complete blood counts and renal function regularly - Avoid use in pregnant women; pregnancy category is unknown - Counsel patients about increased susceptibility to infections and the need for prophylactic measures - Consider vaccination status; live vaccines are contraindicated during treatment - Observe for signs of infusion reactions and be prepared to manage them

Grafalon may interact with other medications that affect immune function or organ systems. Awareness of these interactions helps minimize adverse outcomes.

Avoid: - Live attenuated vaccines during and shortly after therapy - Concurrent use of other T‑cell depleting agents without specialist guidance

Use with caution: - Other immunosuppressants (e.g., calcineurin inhibitors, mTOR inhibitors) - Nephrotoxic drugs (e.g., aminoglycosides, amphotericin B) - Antiviral prophylaxis agents that may increase hepatic load - Medications that prolong QT interval, as electrolyte shifts can occur